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Edited by Gianni CesareniAbstract AML1-ETO fusion protein is observed in approxi-
mately 12% of acute myeloid leukemia. In the present research,
we found that AML1-ETO is able to inhibit Sp1 transactivity.
We also found that this inhibition of Sp1 transactivity by
AML1-ETO is achieved by interaction between Sp1 and RUNT
domain of AML1. AML1b is able to abrogate the inhibition of
AML1-ETO. Since Sp1 is involved in hematopoietic cell diﬀer-
entiation, we proposed that AML1-ETO promotes leukemogen-
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AML1 (RUNX1) is a member of the Runt family of tran-
scription factors. The human AML1 gene generates three alter-
natively spliced variants, AML1a, AML1b, and AML1c.
AML1b and AML1c both possess the DNA-binding region
(RUNT domain) as well as the transcriptional regulatory do-
mains. AML1b and AML1c are therefore considered to be
broadly similar in function. In contrast, AML1a only retains
the DNA-binding domain (RUNT domain), but lacks the
transcriptional regulatory domains. AML1 gene is involved
in chromosomal translocations in leukemia, such as t (8; 21)
results in the formation of AML1-ETO fusion protein. This fu-
sion protein contains most of the ETO protein and the N-ter-Abbreviations: PB, phenylbutyrate; HCK, human hematopoietic cell
kinase; AML, Acute myeloid leukemia
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which is similar to AML1a. AML1-ETO inhibits transcription
of AML1-dependent target genes through ETO moiety and
blocks hematopoietic cell diﬀerentiation [1]. In addition,
AML1-ETO can also interact with other transcription factors
involved in hematopoietic cell diﬀerentiation, such as C/EBP a
and PU.1 [2,3].
Sp1 is a transcription factor involved in hematopoietic cell
diﬀerentiation. In this study, AML1-ETO was found to inhibit
Sp1 transactivity through interacting with Sp1. To our knowl-
edge, this is the ﬁrst report identifying interaction between Sp1
and AML1-ETO. Since Sp1 plays crucial roles in hematopoi-
etic cell diﬀerentiation [4], dysregulation of Sp1 might be
important for AML1-ETO-mediated leukemia development.2. Materials and methods
2.1. Cell culture
CV1 and 293T cells were maintained in Dulbeccos modiﬁed Eagles
medium (GIBCO) with 10% fetal bovine serum at 37 C in a humidi-
ﬁed incubator with an atmosphere of 5% CO2.
2.2. Plasmid construction
The human wild-type p21WAF1/CIP1 promoter luciferase reporter
plasmid, WWP-Luc, was a kind gift from Dr. B. Vogelstein [5]. Its
2.4-kilobase pair genomic fragment containing the transcription start
site was subcloned into the Hind III site of the luciferase reporter vector,
pGL3-Basic (Promega), to generate pWWP [6]. pWP101 reporter plas-
mid was constructed as described previously by K. Nakano. It contains
four Sp1 sites termed Sp1-3, Sp1-4, Sp1-5 and Sp1-6 [6]. pNOSP1 repor-
ter plasmid was constructed as following: A fragment containing the
partial p21WAF1/CIP1 promoter was ampliﬁed from pWWP using
primes as follows: sense, 5 0-CGGGGTACCATTGGCTTTCTGGCC
ATT-30, and antisense, 5 0-CCGGAACCTCGCGTGCT-30. The ampli-
ﬁed fragment containing the sequence between 2320 and 211 of the
p21WAF1/CIP1 promoter was digested with Kpn I endonuclease and
then cloned into the Sma I and Kpn I sites of pWWP. The constructed
pNOSP1 lost 4 Sp1 sites, the Sp1-1, Sp1-2, Sp1-3 and Sp1-4. pWWP,
pWP101 and pNOSP1 were illustrated in Fig. 1A. The hemagglutinin-
tagged Sp1 (identiﬁer of Sp1 in the Uniprot database: P08047-1) expres-
sion vector (pCGNSp1) was the kind gift from Shenk and co-workers
[7]. The pCMV5-AML1-ETO and pCMV5-AML1b (identiﬁer of
AML1b in the Uniprot database: Q01196-1) were kind gifts from Hie-
bert and co-workers [8]. GAL4 DBD/Sp1 was a kind gift from Smale
and co-workers [9]. pCMV5-ETO (identiﬁer of ETO in the Uniprot
database: Q06455-1) and pcDNA3-ﬂag2-AML1a (identiﬁer of AML1a
in the Uniprot database: Q01196-2) were constructed by our lab.2.3. Transient transfection and luciferase assay
3.0 · 105 CV-1 cells or 2.0 · 105 293T cells per well were plated in 6-
well plates. When the cells were 60–80% conﬂuent, they were transfec-
ted by calcium phosphate precipitation technique. pUC19 plasmid wasation of European Biochemical Societies.
Fig. 1. (A) Diagram of pWWP, pWP101 and pNOSP1. pWWP, pWP101 and pNOSP1 were illustrated, containing diﬀerent portion of p21WAF1/
CIP1 promoter. Four Sp1 binding sites in the shadow were deleted in the plasmid. (B) Diagram of AMLa, AML1b, AML1-ETO and ETO. In
comparison with AML1b, AML1a lacks the transcription regulation domain and only contains the RUNT domain. AML1-ETO contains most of
the ETO protein and the N-terminal DNA-binding domain, the RUNT domain of AML1, which is similar to AML1a.
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Phenylbutyrate (PB) was added 24 h after transfection as indicated.
The ﬁnal concentration of PB was 3 mmol/L. Seventy-two hours after
the transfection, cell lysates were collected. The b-galactosidase and
luciferase activities of the cell lysates were measured according to the
instructions from the manufacturer (Promega). The protein concentra-
tion was determined by bicinchoninic acid assay. All assays were car-
ried out at least in triplicate. Each experiment was repeated at least
three times.
2.4. Coimmunoprecipitation and immunoblotting
The cells were fully homogenized by adding buﬀer NE (25 mM Tris
pH 7.5, 0.42 M NaCl, 1.5 mM MgCl2, 0.5 mM EDTA, 1 mM DTT,
25% sucrose). The lysate was incubated on ice for 30 min to solubilize
proteins and cleared by microcentrifuging for 20 min at 4 C. For
immunoprecipitation with AML1 or hemagglutinin antibodies, cell ly-
sate was incubated with 5 ll of AML1 antibody (N-20; Santa Cruz
Biotechnology) or 5 ll of hemagglutinin antibody (Y-11; Santa Cruz
Biotechnology) for 2 h at 4 C. Immunoblotting was performed with
AML1, hemagglutinin or ETO (Ab-1; Calbiochem) antibody and
anti-rabbit or anti-goat antibodies conjugated to horseradish peroxi-
dase.3. Results
3.1. AML1-ETO inhibits Sp1 transactivity
In our previous report, AML1-ETO was found to have weak
inhibitory activity on a 5 0 deletion construct of the p21WAF1/
CIP1 promoter, pWP101 construct [10], which contains four
Sp1 binding sites, but not AML1 binding sites [6,8]. This im-
plied that AML1-ETO might regulate the p21WAF1/CIP1promoter through Sp1 binding sites. To further deﬁne whether
AML1-ETO represses Sp1-mediated transactivation of
p21WAF1/CIP1 promoter, we performed reporter assays using
the pWWP reporter plasmid. As shown in Fig. 2A, Sp1 en-
hanced the pWWP reporter activity (2.25-folds). However,
when Sp1 was co-transfected with AML1-ETO, the pWWP re-
porter activity was repressed (0.78-fold).
By means of HDAC inhibitor to activate endogenous
Sp1 [6,11], transactivity of the p21WAF1/CIP1 promoter was
assessed in CV cells. In the absence of AML1-ETO, HDAC
inhibitor, phenylbutyrate (PB), increased pWWP and
pWP101 luciferase activity by 3.70- and 9.26-folds, respectively
(Fig. 2B and C). Whereas in the presence of AML1-ETO, PB
only increased pWWP and pWP101 luciferase activity by 1.16-
and 2.21-folds, respectively (Fig. 2B and C). But the luciferase
activity of pNOSP1 increased by PB was not aﬀected by
AML1-ETO signiﬁcantly (Fig. 2D). These data suggested that
AML1-ETO inhibits the transcriptional activity of Sp1. To
further conﬁrm this hypothesis, we used another reporter plas-
mid, pGL3-promoter (Promega), in which the ﬁreﬂy luciferase
gene was driven by SV40 promoter containing Sp1 sites. Sp1
was reported to be able to activate SV40 promoter [12]. We
found that AML1-ETO inhibits the PB-mediated activation
of SV40 promoter (Fig. 2E), which is similar to what we found
on p21 WAF1/CIP1 promoter.
By a diﬀerent approach, cDNAs of Sp1 were fused in frame
to the sequences of the DNA binding domain of the GAL4
transcription factor (GAL4 DBD/Sp1). The AML1-ETO and
Fig. 2. AML1-ETO inhibits Sp1 transactivity in CV1 cells. (A) AML1-ETO inhibits Sp1 transactivity in CV1 cells. The diﬀerence between AML1-
ETO and AML1-ETO+Sp1 is not signiﬁcantly (P > 0.05). The diﬀerence between Sp1 and AML1-ETO +Sp1 is signiﬁcantly (P < 0.05). (B–E) Two
hundred and ﬁfty nanograms of expression vector and 300 ng of reporter plasmid were used for transfection. PB treatments were started 24 h after
transfection and generally continued for 48 h. Luciferase activities were normalized by protein concentration for the reason that we failed to ﬁnd a
control reporter construct that is not responsive to Sp1 [11]. The data were presented as activities relative to that of the pWWP (A and B), pWP101
(C), pNOSP1 (D) or pGL3-promoter (Promega) (E), which was not treated with PB, respectively. Each experiment was repeated three times.
*P < 0.05 (F) AML1-ETO inhibits GAL4 DBD/Sp1 transactivity. In the mammalian expression plasmid GAL4 DBD/Sp1, Sp1 is fused with DNA
binding region (amino acids 1–147) of the GAL4 transcription factor. The ﬁreﬂy luciferase reporter plasmid is driven by GAL4 DNA-binding sites.
Luciferase activities were normalized for the b-galactosidase activities in cell lysates. The data were presented as activities relative to that of the ﬁreﬂy
luciferase reporter plasmid. The diﬀerence between empty and GAL4 DBD+ AML1-ETO is not signiﬁcantly (P > 0.05). The diﬀerence between
GAL4 DBD/Sp1 and AML1-ETO+GAL4 DBD/Sp1 is signiﬁcantly (P < 0.05).
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cells together with a luciferase reporter plasmid driven by
GAL4-binding sites. As shown in Fig. 2F, transfection of
GAL4 DBD/Sp1 with the GAL4-responsive target reporter in-
duced signiﬁcantly increased luciferase activity (73.74-folds).Strikingly, co-transfection of AML1-ETO and GAL4 DBD/
Sp1 together repressed the induction of luciferase activity
(7.63-folds) from the GAL4-responsive target promoter, fur-
ther indicating that AML1-ETO represses Sp1-dependent tran-
scription.
Fig. 3. AML1-ETO binds to Sp1 through RUNT domain. 293T cells were transiently transfected with mammalian expression constructs encoding
hemagglutinin-tagged Sp1 and AML1-ETO, AML1a or ETO. Immunoprecipitation (IP) was performed with hemagglutinin (HA) or AML1
antibody. Eight hundred microliters cell lysates were incubated with 5 ll of AML1 antibody. Bound proteins were subjected to immunoblotting with
AML1 or hemagglutinin antibody. Forty microliters total cell lysates were loaded on a SDS–polyacrylamide gel electrophoresis as a control.
Association between AML1-ETO and Sp1 was shown (A). By alternative use of AML1 or hemagglutinin antibodies, the similar association between
AML1-ETO and Sp1 was observed (B). The cells were fully homogenized by adding buﬀer NE + 0.3% Triton X-100, buﬀer NE + 0.3% NP-40 (C) or
buﬀer NE+1 M NaCl (D). The complex of AML1-ETO and Sp1 is resistant to 1 M NaCl, but not to 0.3% Triton X-100 or 0.3% NP-40 (C and D).
AML1a but not ETO associated with Sp1 (E and F). TCL, total cell lysates. AE, AML1-ETO.
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To investigate how AML1-ETO represses Sp1-dependent
transcription, we analyzed whether AML1-ETO is able to bind
to Sp1. 293T cells were transfected with plasmids expressing
AML1-ETO and hemagglutinin epitope-tagged Sp1. In the
coimmunoprecipitation experiments, we observed the associa-
tion between AML1-ETO and Sp1 (Fig. 3A and B). In addi-
tion, the complex of AML1-ETO and Sp1 was resistant to
1 M NaCl, but not to 0.3% Triton X-100 or 0.3% NP-40
(Fig. 3C and D).
AML1a only has RUNT domain and is similar to the por-
tion of AML1 contained in AML1-ETO (Fig. 1B). To identify
the region of AML1-ETO that is responsible for interaction
with Sp1, we transfected 293T cells with plasmids expressing
hemagglutinin epitope-tagged Sp1 and AML1a or ETO. We
found that Sp1 is able to interact with AML1a, but not ETO
(Fig. 3E and F). These indicated that AML1-ETO interacts
with Sp1 through the N-terminus of AML1 including the
RUNT domain, since the RUNT domain constitutes major
part of AML1a. These results support our ﬁndings in tran-
scription activity assays (Fig. 2B–D).3.3. AM L1b is able to abrogate the inhibition of AML1-ETO
competitively
We had shown that both AML1 -ETO and AML1b are able
to bind to both Sp1 protein and AML1 binding sites through
the RUNT domain. Then AML1-ETO and AML1b are able to
compete for binding to them. To determine whether AML1b is
able to abrogate the inhibition of AML1-ETO through compe-
tition, CV1 cells were co-transfected with pWWP, AML1-ETO
and AML1b, then treated with HDAC inhibitor. It was found
that excess dose of AML1b could relief the transcription inhi-
bition mediated by AML1-ETO (Fig. 4). Since both of AML1-
ETO and AML1b are able to bind to Sp1 and AML1 binding
sties, we postulated that AML1b bind to them and prevented
AML1-ETO from binding to AML1 binding sties and Sp1.4. Discussions
Acute myeloid leukemia (AML) is characterized by the
abnormal proliferation and diﬀerentiation of myeloid progen-
itor cells. AML1-ETO fusion protein is observed in approxi-
Fig. 4. AML1b is able to abrogate the inhibition of AML1-ETO competitively: diﬀerent amounts of expression vector and reporter plasmid, pWWP,
were used for transfection. PB treatments were started 24 h after transfection and generally continued for 48 h. Luciferase activities were normalized
by protein concentration for the reason that we failed to ﬁnd a control reporter construct that is not responsive to Sp1. The data were presented as
activities relative to that of the pWWP, which were not treated with PB. Each experiment was repeated three times. *Compare with empty group
P < 0.05. # Compare with AML1-ETO group. P < 0.05.
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in leukemia development. The biological feature of AML1-
ETO has shown that it has many eﬀects on leukemogenesis
[13,14]. To understand the molecular mechanism of AML1-
ETO in leukemogenesis, we investigated how AML1-ETO af-
fects p21WAF1/CIP1 and transcription factor Sp1.
In this report, we demonstrated that AML1-ETO, AML1a
and AML1b all inhibit the PB induced luciferase activity of
pWP101 (Fig. 2C). Hence we postulated that RUNT domain
is necessary for this inhibition eﬀect since AML1-ETO, AML1a
and AML1b all have RUNT domain. ETO moiety in the
AML1-ETO fusion protein is able to enhance this inhibition ef-
fect since AML1-ETO has most potent inhibition eﬀect on Sp1
(Fig. 2B andC).Neither AML1a norAML1b represses the lucif-
erase activity of pWWP increased by PB. But both AML1a and
AML1b inhibit the luciferase activity of pWP101 increased by
PB. We thought that the 2.4-kilobase pair wild-type
p21WAF1/CIP1 promoter is regulated by more transcription
factors than pWP101. pWP101 contains the luciferase reporter
gene driven by only 101 bp upstream of the transcription start
site of p21WAF1/CIP1. It maybe has no transcription factor
binding sites other than Sp1. pWP101 activity is more depen-
dent on Sp1 than pWWP. Therefore AML1a and AML1b only
inhibit the luciferase activity of pWP101 increased by PB, but
not the luciferase activity of pWWP.
The previous reports had found that Sp1 is a transcription
factor involved in hematopoiesis. Sp1 transactivity increased
in decitabine and Vitamin D3 induced diﬀerentiation of leuke-
mia cells [4]. The human hematopoietic cell kinase (HCK) is
speciﬁcally expressed in myeloid cells and to a minor extent
in B-lymphoid cells. Sp1 up-regulates HCK expression at the
transcriptional level during myeloid diﬀerentiation of hemato-
poietic cells [15]. All these data indicate that Sp1 is a transcrip-
tion factor involved in hematopoietic cell diﬀerentiation. Here,
we demonstrated that AML1-ETO inhibited Sp1 transactivity
signiﬁcantly. AML1-ETO might block hematopoietic cell dif-
ferentiation through suppressing Sp1 transactivity.
In conclusion, we found that AML1-ETO, through its
RUNT domain, interacts with Sp1 and inhibits Sp1 transactiv-
ity. This provides a novel mechanistic explanation for AML-
ETO mediated diﬀerentiation block, which represents an
important step towards transformation of t (8; 21) leukemia.Acknowledgements: We thank Doctor M. Ohki for providing pBlue-
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